The patient support programs earning the strongest marks from physicians, practice-based staff, and patients are not necessarily those offering the most services, but those that most effectively ...

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world. The drugmaker will cut ...

Keytruda is a prescription drug that’s given as an intravenous (IV) infusion (and injection into a vein over a period of time). Learn about how the drug is given, how often you’ll receive doses, and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A global investigation reveals how the high price of Merck’s blockbuster cancer drug Keytruda locks out patients in ...

Most people take Keytruda for about 2 years, but this can change depending on how well it works and the side effects experienced. After stopping, it usually takes about 4 months for Keytruda to leave ...

The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The U.S. Food and Drug Administration has approved Merck's Keytruda (pembrolizumab) plus chemotherapy as treatment for adult patients with primary advanced or recurrent endometrial carcinoma. This is ...

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow. Sales rose 5% to $16.29 billion, boosted by 12% ...

For all its success across a wide range of cancer types, Merck’s PD-1 superstar Keytruda has never been able to crack the code for one of the toughest-to-treat indications in oncology—ovarian cancer.

Monday - Friday, 6:00 - 7:00 PM ET Merck CEO Rob Davis said the drugmaker has evolved beyond Keytruda, with more than 20 potential blockbuster launches over the next five years. He said years of R&D ...